Dow Jones

50 326,48

-1,07%

DAX

Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.

Accueil
Investir
Actions
Etats-Unis
NASDAQ
GeneDx Holdings Corporation (WGS)
GeneDx Holdings Corporation (WGS) Actualités

GeneDx Holdings Corporation (WGS)

56,32

-0,01

( -0,02% )

Mis à jour : 18:51:08

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

GeneDx to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that company...

GeneDx Reports First Quarter 2026 Financial Results and Updates Full-Year Outlook

Reported total revenue of $102.3 million with 27% year-over-year growth in exome and genome revenue Reported exome and genome volume growth of...

GeneDx to Report First Quarter 2026 Financial Results on Monday, May 4, 2026

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced it will...

Landmark Study Shows Average Cost Savings of $80,000 Per Child and Overall Improved Health Outcomes Following GeneDx Exome and Genome Testing

New data shows up to 61% reduction in healthcare costs for children with neurodevelopmental disorders in the 12 months following ExomeDx™ and...

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

Program to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC GeneDx (Nasdaq: WGS...

GeneDx to Present 18 Abstracts at ACMG 2026, Showcasing the Scale of GeneDx Infinity™ and Real-World Genomic Leadership

GeneDx showcases leadership in exome and genome quality, expanded access through non-genetics ordering, and AI-driven innovations that enhance...

GeneDx to Participate in Upcoming Investor Conferences

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that company...

INSERTING and REPLACING GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026

Reported fourth quarter 2025 revenues of $121.0 million with 32% year-over-year growth in exome and genome test revenue (42% excluding a...

GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026

Reported fourth quarter 2025 revenues of $121.0 million with 32% year-over-year growth in exome and genome test revenue (42% excluding a...

TIME Names GeneDx CEO Katherine Stueland to the 2026 TIME100 Health List of the World’s Most Influential Leaders in Health

Recognition highlights growing global impact of rare disease diagnosis and the role of genomics in...

GeneDx Announces Preliminary 2025 Financial Results and Provides 2026 Guidance

Expects full year 2025 revenues of $427 million, with exome and genome revenue up 54% (58% excluding a one-time 2024 benefit) Expects fourth...

GeneDx and Komodo Health Partner to Build the World’s Most Complete Longitudinal Rare Disease Dataset

GeneDx’s Infinity™ will leverage insights from Komodo’s Healthcare Map® to unlock faster health economics and outcomes research (HEOR), biopharma...

GeneDx Announces GenomeDx Prenatal™, Expanding Industry-Leading Genomic Diagnosis Into Prenatal Care

New whole genome sequencing test delivers fast, comprehensive insights when fetal anomalies are identified, reinforcing GeneDx’s commitment to...

GeneDx Appoints Dr. Linda Genen as Chief Medical Officer to Accelerate the Future of Genomic-First Care

Recognized neonatologist and payer-strategy leader joins GeneDx to expand earlier diagnosis and establish...

GeneDx Leads Rare Disease Genomics with Unmatched Research and Clinical Impact in 2025

Industry-leading research powered by GeneDx Infinity™ accelerates the transition of genomics from discovery to the standard of clinical care...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Allied Security Innovati... (EM)

Nuveen California AMT Fr...

NASDAQ

MYIE

INNOVATION ECONOMY CORP

NASDAQI

DECO

SPDR Galaxy Digital Asse...

TSXV

LMD

LED Medical Diagnostics

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

Vous avez déjà un compte? Connexion

Vous n'avez pas de compte ? Inscription

En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

GeneDx Holdings Corporation (WGS)

Outils de qualité professionnelle, pour des investisseurs individuels.